Articles
Exjade 500 mg, dispergierbare Tabletten

Exjade 500 mg, dispergierbare Tabletten

7680574660119 CH-57466 Tabletten

Associated product:

EXJADE cpr disp 500 mg 84 pce

No image available

Article details

Package size: 84
Selling units: 84
Measure: Tablette(n)
Galenic form: Tabletten
Galenic group: Tabletten

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics

Allemand

06/04/2022

Summary of Product Characteristics

Français

06/04/2022

Summary of Product Characteristics

Italien

06/04/2022

Patient information leaflet

Allemand

25/08/2020

Patient information leaflet

Français

25/08/2020

Patient information leaflet

Italien

25/08/2020

Detailed composition

Substance	Quantity	Type	Category
deferasiroxum	500.0 MG	Substance	Wirkstoff (Principe actif)
crospovidonum	-	Substance	HNIDK
lactosum monohydricum	543.6 MG	Substance	HBESI
cellulosum microcristallinum	-	Substance	HNIDK
povidonum K 30	-	Substance	HNIDK
natrii laurilsulfas	-	Substance	Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
silica colloidalis anhydrica	-	Substance	HNIDK
magnesii stearas	-	Substance	HNIDK
natrium	0.68 MG	Substance	HBESI

Authorization holder

Novartis Pharma Schweiz AG

6343 Risch

Authorization information

Swissmedic authorization number: 57466
Drug name: Exjade, dispergierbare Tabletten
Galenic form: TABSU
ATC Code: V03AC03
Authorization status: Z
Dispensing category: B
First authorization: 03/11/2005
Authorization expiration date: 31/12/9999
IT Number: 06.99.0.
Domain: Human medicine

Field of application

Behandlung der transfusionsbedingten Hämosiderose. Behandlung von chronischer Eisenüberladung, die eine Chelattherapie erfordert, bei Patienten mit nicht-transfusionsabhängiger Thalassämie ab 10 Jahren.